Business Context and Reporting Period
This Form 8-K Current Report was filed by Supernus Pharmaceuticals, Inc. on March 21, 2022. The report addresses a compliance issue regarding the delayed filing of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on regulatory compliance status rather than financial performance data.
Material Changes and Events
- Late Filing Notification: On March 1, 2022, the Company filed a Form 12b-25 notifying the SEC of a delay in filing its 2021 Annual Report.
- Nasdaq Non-Compliance: On March 17, 2022, Nasdaq issued a letter stating the Company was not in compliance with Rule 5250(c)(1) due to the failure to timely file the Annual Report.
- Delisting Risk: The Company faces potential delisting if it fails to regain compliance within the specified timeframe.
Guidance, Outlook, and Risks
Compliance Plan: The Company anticipates filing its Annual Report on or before April 4, 2022, which would allow it to regain compliance with Nasdaq listing requirements.
Regulatory Timeline: Nasdaq rules permit the Company to submit a plan to regain compliance by May 16, 2022. If accepted, an exception of up to 180 calendar days (until September 12, 2022) may be granted.
Risks and Contingencies: The filing highlights risks related to the Company's ability to complete its financial statements and the assessment of internal controls over financial reporting. Additionally, there is uncertainty regarding the ability of the independent auditor, KPMG LLP, to complete its audit procedures.
Investor Verification Checklist
- Verify the actual filing date of the Form 10-K for the fiscal year ended December 31, 2021.
- Confirm the Company's current listing status on The Nasdaq Stock Market.
- Review the upcoming Form 10-K for details on the audit completion and internal control assessments.
- Monitor for any further communications from Nasdaq regarding the compliance plan or extension requests.